Artemis Targets EBITDA Above 20% Despite Raipur Losses

Artemis Medicare Services Limited — Q4 & FY26 Earnings Call (May 11, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “strong performance,” “confident,” and “well positioned to drive further growth.”
• Forward-looking language is assertive: “We are confident,” “will be on track,” “exciting year,” and “EBITDA northwards of 20% if not more.”
• Even when discussing Raipur losses, they frame it as contained and offset by Gurgaon leverage (“EBITDA growth will continue… despite losses in Raipur”).

2. Key Themes from Management Commentary

• Strong FY26 growth and profitability expansion
• FY26 revenue from operations: INR 1,081 cr (+15.4% YoY)
• FY26 EBITDA: INR 218 cr; margin 20.2%
• FY26 PAT: INR 104 cr (+26.2% YoY)
• Gurgaon as the margin engine
• Q4 occupancy 64.6%; ARPOB INR 84,571 (+7.3% YoY)
• Management expects EBITDA >20% and ongoing margin improvement via case mix, efficiency, and corporate cost dilution.
• International patient resilience + diversification
• International patients grew 26.9% in FY26 despite West Asia war.
• Strategy to keep international revenue share at ~30–31% “irrespective of where we are.”
• Q4 international dip in March (war impact) is described as recovered to ~90% by May.
• Expansion pipeline with clear commissioning milestones
• Raipur 300-bed: on track for Q1 FY27 operations.
• South Delhi 650-bed: expected commissioning in FY29.
• Capacity target: expand from 800 beds to 2,000 beds by 2029.
• Digital/AI and operational efficiency as a core lever
• AI-assisted triage systems to reduce wait times and improve patient flow.
• Data analytics to optimize pathways.
• Cost management + disciplined capital allocation
• Board approval for fundraising up to INR 700 cr to support expansion.
• Project evaluation framed around ROCE (16–18%) and payback (5–6 years).

3. Q&A Analysis

Theme A: Gurgaon performance—occupancy, margins, and ARPOB

• Core questions
• Can Gurgaon maintain/improve high EBITDA margins into FY27–FY28?
• Can occupancy rise above the historical 63–64% range (toward 70%)?
• What drives margin improvement (efficiency, case mix, corporate cost dilution)?
• Management response
• Margin: “We will not only try to maintain it, but we will try to better it.”
• Occupancy ramp: opening additional beds when occupancy hits 70%; target 70–75%.
• Raipur impact on consolidated margins: expects only a ~1% to 1.5% EBITDA drag initially.
• Margin drivers explicitly listed: high-end patient mix, consumption down 1.5%–2%, and corporate cost spread across multiple facilities.
• Notable/strong answers
• Very specific operational trigger: “The moment we have 70% occupancy for a quarter, we are going to be opening 50 then another 50 beds.”
• Quantified margin outlook: “Gurugram facility will see EBITDA northwards of 20% if not more.”

Theme B: Raipur ramp-up—losses, breakeven, bed operationalization

• Core questions
• How much loss from Raipur will hit EBITDA in FY27?
• When will Raipur beds become operational (phasing)?
• What is capex per bed and ARPOB expectations?
• Management response
• Losses: INR 18–20 cr losses expected; consolidated EBITDA drag ~1%–1.5%.
• Operationalization: first phase 150 beds in Q1 FY27; within 2 quarters expect all 300 beds operational.
• Capex: ~INR 110–120 cr for 300 beds (also stated earlier as INR 18–20 cr losses until break-even).
• ARPOB: INR 33,000–35,000+ long run; start around 35,000.
• Evasive/partial elements
• Some capex details were consistent (per-bed ballparks), but ARPOB vs margin sustainability was defended more qualitatively than with a full model.
• Competitive intensity in Raipur was addressed with confident narrative (“mini-Lucknow”), but without hard occupancy/market share data.

Theme C: International patients—war impact, geography mix, and pricing

• Core questions
• What happened to international patient growth in Q4 (March dip) and what’s the current trend?
• How much of international is Middle East vs other regions?
• How is pricing/ARPOB growth achieved given insurer/TPA negotiations?
• Management response
• March dip: 15–18% dip in international patients; recovery in April; by May ~90% recovery.
• Middle East share: ~30% of international.
• Pricing growth: incremental pricing 3–5% nominal, but effective ~3% due to TPA/insurer locking; management claims ARPOB growth mainly via case mix + efficiency.
• Notable/strong answers
• “Unless something new happens, we are back on track” (clear conditional confidence).
• International share target: 30–31% maintained “irrespective” of top-line movement.

Theme D: VIMHANS / South Delhi capex, phasing, and fundraising rationale

• Core questions
• Capex per bed and phasing for South Delhi (VIMHANS).
• How much of fundraising is for new projects vs existing ones; why raise INR 700 cr if debt/internal accruals exist?
• Management response
• South Delhi capex: ~INR 500 cr total for 650 beds (stated as INR 75–80 lakhs per bed; land/building owned by trust; interiors/equipment by Artemis).
• Fundraise rationale: deposits for trust-land projects cannot be funded through debt; fundraise supports projects beyond the three in-hand (management said “only going to fund our new projects which could be one or which could be two”).
• Capital allocation metrics: ROCE 16–18%; payback 5–6 years.
• Potential red flag in Q&A
• Fundraise use is described as both (a) supporting expansion broadly and (b) specifically for “new projects beyond the three.” This is not fully reconciled with earlier statements that fundraising also supports expansion initiatives.

Theme E: Regulatory/policy risks—tariffs, margin caps, CGHS

• Core questions
• Any concrete risk of margin caps on medical devices / healthcare?
• CGHS tariff revisions—impact on margins?
• Management response
• Margin caps: “No… nothing concrete,” last time was stents/implants.
• CGHS: management says pricing improved; also frames government mix management as strategic (avoid empty beds; “cherry picking” investigations closer to rack rates).

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY26 actuals (management-reported)
• Revenue from operations: INR 1,081 cr (+15.4% YoY)
• EBITDA: INR 218 cr; margin 20.2%
• PAT: INR 104 cr (+26.2% YoY)
• Gurgaon
• EBITDA: “northwards of 20% if not more” (coming years)
• Occupancy: target 70–75%; bed opening tied to 70% occupancy
• Raipur
• Losses: INR 18–20 cr until break-even
• EBITDA drag on consolidated: ~1% to 1.5% lower in FY27 (initially)
• Break-even timeline: 18–20 months (also referenced as 18–24 months in Q&A)
• Bed ramp: 150 beds operational in Q1 FY27, then full 300 beds within 2 quarters
• International
• International revenue share target: 30–31% (maintain irrespective of top-line movement)
• Middle East share within international: ~30%
• Capacity
• Expansion target: 2,000 beds by 2029
• Raipur commissioning: Q1 FY27
• South Delhi commissioning: FY29
• Fundraising
• Board approval: up to INR 700 cr

Implicit signals (qualitative)

• Management expects continued EBITDA growth in FY27 despite Raipur losses, driven by Gurgaon operating leverage.
• Pricing is not the primary growth lever; case mix + efficiency are emphasized.
• International demand is resilient but conditional (“unless something new happens”).

5. Standout Statements (direct / highly revealing)

• On Raipur drag vs consolidated growth
• “EBITDA growth will continue… despite losses in Raipur.”
• “EBITDA maybe a 1% to 1.5% lower because of these losses.”
• On Gurgaon margin ambition
• “Gurugram facility will see EBITDA northwards of 20% if not more.”
• On occupancy-to-bed opening mechanism
• “The moment we have 70% occupancy for a quarter, we are going to be opening 50 then another 50 beds.”
• On international resilience
• “Unless something new happens, we are back on track.”
• “Our endeavour would be to remain at the same 30%, 31% of revenue coming from international patients.”
• On fundraising necessity
• “We need the fundraise because… we also have to give them a deposit. The deposit is cannot be funded through debt.”
• On competitive positioning
• “There is no deficiency in this hospital” (Gurgaon capability vs best-in-NCR).

6. Red Flags / Positive Signals

Positive signals
– Clear operational triggers (70% occupancy → bed rollout) and quantified Raipur drag.
– Strong profitability metrics and margin expansion narrative supported by FY26 results.
– International recovery after March dip is time-bound and monitored.

Red flags / watch-outs
– Guidance consistency risk: Raipur break-even timing varies slightly across answers (18–20 months vs 18–24 months).
– Fundraise rationale complexity: fundraising described as supporting “new projects beyond the three,” but earlier call framing also ties it to expansion broadly—could create investor confusion on deployment.
– Market risk narrative reliance: Raipur competitive demand is asserted (“mini-Lucknow”) without hard evidence; could be optimistic.
– Cash flow discussion not fully reconciled: CFO states cash conversion and no one-offs, but another question suggests CFO came off in second half; management offered to check offline.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls provided)

a. Change in Tone Over Time

• Shift: More Optimistic
• Q2 FY26 (Nov 2025): management emphasized “steady growth,” but with more “looking ahead” and cautious framing around ramp-up and break-even.
• Q3 FY26 (Feb 2026): still confident, but margins were described as improving with occupancy ramp and cost easing.
• Q4/FY26 (May 2026): tone becomes more assertive with stronger quantified outcomes (FY26 profitability, EBITDA >20% expectations, and “confident” navigation of tariff challenges).
• What changed
• More confidence in margin sustainability (“northwards of 20%”).
• More operational specificity (bed opening triggers, Raipur phasing).

b. Tracking Past Commitments vs Outcomes

1) Raipur commissioning timeline
– Past statement (Nov 2025 / Feb 2026):
– “on track for commissioning by the end of FY26” and “expected to begin operations from April-May 2026” (Q3 FY26 call).
– Current call (May 2026):
– “Raipur… on track to commence operations in Q1 of FY27.”
– Assessment: ✅/⏳ Mostly delivered but slightly shifted (from April-May to Q1 FY27).

2) Gurgaon occupancy improvement to ~70%
– Past statement (Feb 2026):
– “hovering around 68%-70% by the end of this financial year.”
– Current call:
– Q4 occupancy 64.6%; management now says bed rollout at 70% and expects reaching 70–75% by Q2 FY27.
– Assessment: ⏳ Delayed (70% target not yet achieved by Q4 FY26).

3) Daffodils/Cardiac care profitability
– Past statement (Feb 2026):
– Losses were being addressed; expectation that losses would reduce and centers would break even.
– Current call:
– “Daffodils and cardiac care are all EBITDA break even and making small profits. So that’s actually a non-issue.”
– Assessment: ✅ Delivered (at least narrative-wise; no hard segment numbers provided in Q4 call).

4) Fundraise INR 700 cr
– Past statement (Feb 2026):
– Board agreed to fundraise INR 700 cr; details to follow.
– Current call:
– Board approval reiterated; fundraising used to support expansion; deposits for trust-land projects emphasized.
– Assessment: ✅ On track as a plan, but deployment specifics remain partly fluid.

c. Narrative Shifts

• From “occupancy ramp” to “margin engine + operating leverage”
• Earlier calls leaned heavily on occupancy and cost dissipation as towers mature.
• Now, management leans more on efficiency (consumption down) and corporate cost dilution to sustain margins.
• Raipur risk framing becomes more quantified
• Earlier: “losses not big / 1–1.5 years break-even.”
• Now: explicit INR 18–20 cr losses and 1–1.5% EBITDA drag.

d. Consistency & Credibility Signals

• Medium credibility
• Strength: repeated use of quantified ranges (losses, drag, capex per bed, occupancy triggers).
• Weakness: some timelines and numbers shift slightly (Raipur break-even 18–20 vs 18–24 months; occupancy target not yet met by Q4).
• Management often provides confident directional answers, but occasionally relies on “we’ll see” / “unless something new happens.”

e. Evolution of Key Themes

• Demand / international
• Improving/stable: international share target maintained; war impact treated as temporary and recovered.
• Margins
• Improving: FY26 margin 20.2% and expectation of Gurgaon EBITDA >20% “if not more.”
• Expansion
• Stable execution narrative: Raipur Q1 FY27, South Delhi FY29, capacity to 2,000 by 2029.
• Regulatory
• Risk acknowledged (tariff adjustments) but mitigated via “operational agility” and “strategic cost management.”

f. Additional Insights (cross-period)

• The company’s core growth thesis is increasingly Gurgaon-led while Raipur is treated as a controlled drag rather than a growth driver in FY27.
• Management’s emphasis on efficiency (consumption down 1.5%–2%) suggests they are trying to protect margins even if occupancy ramp is slower than earlier implied.
• Fundraise justification now includes deposit constraints (trust-land projects), which is a more specific operational constraint than previously discussed—suggesting capital planning is becoming more complex as they move into new geographies/structures.